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Understanding  the  source  of  drug  resistance  emerging  within  a treated  patient  is an  important  problem,
from  both  clinical  and  basic  evolutionary  perspectives.  Resistant  mutants  may  arise  de  novo  either  before
or  after  treatment  is  initiated,  with  different  implications  for prevention.  Here  we  investigate  this  problem
in  the  context  of  chronic  viral  diseases,  such  as human  immunodeﬁciency  virus  (HIV)  and hepatitis  B and  C
viruses  (HBV  and  HCV).  We  present  a uniﬁed  model  of  viral  population  dynamics  within  a host,  which  can
capture  a variety  of viral  life  cycles.  This  allows  us to identify  which  results  generalize  across  various  viralIV
epatitis B
epatitis C
volutionary rescue
ife  cycle
tochastic process
diseases,  and which  are  sensitive  to  the  particular  virus’s  life  cycle.  Accurate  analytical  approximations
are  derived  that  allow  for  a solid  understanding  of  the  parameter  dependencies  in  the  system.  We  ﬁnd
that  the  mutation-selection  balance  attained  prior  to treatment  depends  on  the  step  at  which  mutations
occur  and  the viral  trait  that  incurs  the  cost of  resistance.  Life  cycle  effects  and  key  parameters,  including
mutation  rate,  infected  cell  death  rate,  cost  of resistance,  and  drug  efﬁcacy,  play  a  role  in  determining
when  mutations  arising  during  treatment  are  important  relative  to  those  pre-existing.
.ntroduction
Over the past two decades, the advent of highly effective antivi-
al drugs has revolutionized the treatment of chronic viral diseases,
ncluding human immunodeﬁciency virus (HIV) and hepatitis B
nd C viruses (HBV and HCV). These drugs have been successful in
ubstantially reducing morbidity, mortality and transmission, but
nfortunately they also impose a strong selection pressure, which
as led to observations of drug resistance and associated treatment
ailure (Hirsch et al., 2008; Johnson et al., 2011). The emergence
f drug resistance can be attributed to the remarkable potential
f these viruses for rapid adaptation, due to characteristics such
s a large population size, fast replication and a high mutation
ate. The rapid accumulation of genetic diversity has the important
onsequence that many drug-resistant mutants are likely to exist
lready by the time treatment begins (Cofﬁn, 1995). More generally,
t has been pointed out that drug resistance may  emerge from two
ources: mutants pre-existing when treatment starts, or those gen-
rated de novo during residual replication under treatment (Ribeiro
nd Bonhoeffer, 2000). Distinguishing between these two sources
f resistance has implications for treatment strategies. Treatment
ailure due to de novo mutants could be curtailed by a higher drug
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dose, minimizing ongoing replication of the drug-sensitive strain.
The selection of pre-existing mutants, on the other hand, could be
better avoided by combination therapy to which fewer mutants are
resistant (Ribeiro and Bonhoeffer, 2000).
The source of resistance is, however, difﬁcult to infer clini-
cally. The detection of minority variants is limited by the extent of
sampling and by the sensitivity of assays, making it challenging to
detect rare variants and pinpoint when mutants ﬁrst arise. Thus,
mathematical models play an important role in understanding
the problem. Several previous studies have investigated the con-
tributions of pre-existence and/or production during treatment to
the emergence of intra-host drug resistance, with varying degrees
of theoretical development and quantiﬁcation of speciﬁc scenar-
ios. These have primarily dealt with HIV (Bonhoeffer and Nowak,
1997; Bonhoeffer et al., 1997; Ribeiro et al., 1998; Ribeiro and
Bonhoeffer, 1999, 2000; Ribeiro, 1999; Roberts and Ribeiro, 2001;
Gadhamsetty and Dixit, 2010; Shiri and Welte, 2011; Pennings,
2012), while the issue of pre-existing resistant variants has been
analysed only to a limited extent in HCV models (Rong et al., 2010;
Adiwijaya et al., 2010). Relatively few of these studies (Bonhoeffer
and Nowak, 1997; Bonhoeffer et al., 1997; Ribeiro, 1999; Ribeiro
and Bonhoeffer, 2000; Pennings, 2012) consider both pre-existence
and production during treatment together. The most systematic
Open access under CC BY-NC-ND licensetheoretical comparison to date (Ribeiro and Bonhoeffer, 2000) con-
cluded in the case of HIV that, over wide ranges of parameter space,
pre-existence of resistant mutants is more likely than produc-
tion after treatment begins. Exceptions occurred only when drug
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fﬁcacy was low or the cost of resistance was moderate to high
Ribeiro and Bonhoeffer, 2000).
Although questions regarding the source of resistance have pri-
arily been addressed in the context of HIV, this issue is also
elevant to other chronic viral pathogens, such as HBV and HCV.
lthough these viral infections share many similar features, there
re also a number of qualitative and quantitative differences among
he viruses’ life cycles. For instance, the error-prone replication step
iving rise to most mutations occurs in the production of virions
or HBV and HCV, versus the integration of the provirus in HIV
Ganem and Schneider, 2001; Lindenbach and Rice, 2001; Mansky
nd Temin, 1995). Furthermore, infected cells are much longer-
ived in HBV than in HIV (Nowak et al., 1996; Ribeiro et al., 2002;
oriano et al., 2008). We  are therefore interested in determining
hether the results obtained for HIV can be extended to viruses
ith different life cycles and drugs with different modes of action.
Despite differences in viral life cycles, models describing the
ynamics of HIV, HBV and HCV have a similar structure (Nowak
nd May, 2000; Perelson, 2002; Ribeiro et al., 2002). It is thus a
atural step to develop a single model that attempts to account for
ifferent viral life cycles in a more general framework. We  focus
n a stochastic model, capturing the effects of rare mutations and
mall population sizes. Earlier work on pre-existence and emer-
ence was initially limited to deterministic models (Bonhoeffer and
owak, 1997; Bonhoeffer et al., 1997; Ribeiro et al., 1998). Later
tochastic models of the treatment phase did not analyse the role of
tochastic loss of beneﬁcial mutants (Ribeiro and Bonhoeffer, 2000;
oberts and Ribeiro, 2001), or investigated this factor only to a
imited extent (Pennings, 2012). Here we develop robust analytical
pproximations for a stochastic model, which allow us to identify
ey parameter dependencies and readily explore parameter space,
hus investigating the generality of our ﬁndings.
In the following section, we present a uniﬁed viral dynamics
odel. We  then develop analytical approximations to the proba-
ility of resistance emerging from mutants arising before or after
reatment begins. In this framework, we can explore the impact of
arious parameters as well as structural differences in life cycles,
ncluding the mechanisms of mutation, cost of resistance, and drug
ction. We  investigate the situations in which mutants pre-existing
nd/or arising during treatment make a substantial contribution,
nd also consider the speed with which resistance rises during
reatment. We  conclude with a discussion of these ﬁndings in light
f the differences among HIV, HCV, and HBV, as well as the more
eneral problem of drug resistance in pathogens.
odel
We expand upon a model of intra-host viral dynamics which has
een used widely in the literature, see e.g. Nowak and May (2000),
erelson (2002), including in previous studies of pre-existence and
mergence in HIV (Bonhoeffer and Nowak, 1997; Bonhoeffer et al.,
997; Ribeiro et al., 1998; Ribeiro and Bonhoeffer, 1999, 2000;
ibeiro, 1999; Roberts and Ribeiro, 2001) and HCV (Rong et al.,
010; Adiwijaya et al., 2010). Besides facilitating comparison with
uch previous work, this population dynamics framework pro-
ides a convenient and natural representation to capture life cycle
etails. Nonetheless, alternative approaches could also be used to
escribe such a system; for instance, a few previous studies of drug
esistance in HIV have modelled populations in discrete time steps
ith given ﬁtness values (Gadhamsetty and Dixit, 2010; Pennings,
012) and made use of results from population genetics (Pennings,
012).
For two strains of virus, we model ﬁve populations: uninfected
arget cells (x), cells infected by the drug-sensitive (wild type)
train (yS), cells infected by the drug-resistant (mutant) strain (yR),idemics 4 (2012) 187–202
drug-sensitive  free virions (vS) and drug-resistant free virions (vR).
We generalize from previous work to allow any virus-related
parameters to be strain-speciﬁc, and for mutations to happen at
either the cell infection step or the virion production step. We
suppose that the drug(s) work by blocking these same steps. For
completeness, we also include the loss of free virions during infec-
tion events. Then the ODE form of the model is:
x˙ =  − dx − ˇS(1 − I)xvS − ˇRxvR (1a)
y˙S = ˇS(1 − I)(1 − uI)xvS + ˇRuIxvR − aSyS (1b)
y˙R = ˇS(1 − I)uIxvS + ˇR(1 − uI)xvR − aRyR (1c)
v˙S = −ˇSxvS + kS(1 − P)(1 − uP)yS + kRuPyR − cSvS (1d)
˙vR = −ˇRxvR + kS(1 − P)uPyS + kR(1 − uP)yR − cRvR (1e)
The parameters of this model are the target cell production rate, ;
the target cell natural death rate, d; the strain-speciﬁc infectivities,
ˇS and ˇR; the infected cell death rates, aS and aR; the virion pro-
duction rates, kS and kR; and the free virion clearance rates, cS and
cR. For simplicity, we assume in the following that  is a constant.
More generally,  can be taken as a function of (x, yS, yR), as has been
done for example in hepatitis where the homeostatic proliferation
of hepatocytes can be signiﬁcant (Dahari et al., 2007; Guedj et al.,
2010; Rong et al., 2010).
We  model mutation according to a “stamping machine” mode
of replication (Sanjuán et al., 2010; Loverdo et al., 2012), in which
the mutation rates are uI at the infection step and uP at the virion
production step. Depending on the life cycle of a particular virus,
setting either uI = 0 or uP = 0 may  be more appropriate. For instance,
for a retrovirus such as HIV the major source of mutations is
reverse transcription of viral RNA into proviral DNA, prior to inte-
gration into the host genome, by an error-prone viral enzyme (Goff,
2001; Mansky and Temin, 1995). This would be represented by
uI > 0, accounting for mutations in the formation of an infected
cell, and uP ≈ 0 since transcription of RNA for progeny virions uses
a host enzyme (Goff, 2001), which is of higher ﬁdelity. Indeed,
HIV-speciﬁc multi-strain models that explicitly include free viri-
ons, including Bonhoeffer et al. (1997), typically include mutation
only at the cell infection step. On the other hand, for hepati-
tis C, the error-prone steps using viral polymerases occur in the
production of individual progeny virions (Lindenbach and Rice,
2001). Although the life cycle includes in part binary (not only
stamping machine) replication (Sanjuán et al., 2010), taking uP > 0
and uI = 0 in our framework seems a reasonable ﬁrst approxima-
tion, which has been used previously in multi-strain HCV models
(Rong et al., 2010; Adiwijaya et al., 2010; Guedj and Neumann,
2010).
By modelling only two strains of virus, we suppose that the over-
all mutation rate, u ≡ uI or uP, is an effective rate accounting for
whatever underlying genetic change confers drug resistance. For
instance, if n site changes are required, taking u = u˜n, where u˜  is
the per-site mutation rate, is a good approximation if all interme-
diate strains have low ﬁtness (which would typically be the case
under combination drug treatment). If any of n single site changes
from the wild type confer resistance, with all resistant strains hav-
ing similar properties, then u ≈ nu˜.  More generally, an appropriate
re-scaling of mutation rate should be able to capture the mean rate
of mutational ﬂow from wild type to fully resistant; however, we
do not expect to capture higher moments. Details of the mutational
pathway(s) to full resistance may  indeed be important, but also
add many parameters to the system. As a ﬁrst approach, we thus
make the approximation of two  strains with an effective mutation
rate.
Treatment is modelled by drug action at two  possible steps of
the replication cycle. A drug that blocks infection of target cells,
such as an entry, reverse transcriptase or integrase inhibitor for
er / Ep
H
a
a
b
p
s
S
s
p
i
f
s
b
v
i
g
a
s
n
m
u
i
o
b
c
P
a
a
t
t
t
s
2
t
e
t
a
(
v
t
m
g
s
G
g
t
t
k
a
m
v
b
t
s
e
d
i
c
s
l
a
t
t
cH.K. Alexander, S. Bonhoeff
IV, reduces the successful infection rate of the sensitive strain by
 factor I, called the efﬁcacy. We  assume that the free virion is
lways lost in an “attempted” infection, whether or not blocked
y drug. A drug that blocks production of viable virions, such as a
rotease inhibitor for HIV or HCV, reduces the rate at which drug-
ensitive infected cells produce (viable) virions by the efﬁcacy P.
ome drugs, such as lamivudine for HBV, may  exert effects at both
teps (Nowak et al., 1996; Ribeiro et al., 2002). If a drug is not
resent, the corresponding efﬁcacy is set to zero, while the max-
mal efﬁcacy is one. We  assume here that the resistant strain is
ully resistant, and thus the factors of (1 − ) are applied only to the
ensitive strain.
We  quantify ﬁtness of a strain by its basic reproductive num-
er, R0, in the corresponding single strain model. For an intra-host
iral disease, R0 can be deﬁned as the expected number of new
nfected cells produced in one cycle of replication from a sin-
le infected cell introduced to an uninfected population (Nowak
nd May, 2000). The basic reproductive number of the sensitive
train in the absence of drug is thus R00 = (ˇSkS)/(daScS), if we
eglect loss of free virions when infecting cells (this approxi-
ation is discussed below). In practice, we take drug efﬁcacies
nder treatment sufﬁciently high such that RS0 = R00(1 − I)(1 − P)
s less than one. The resistant strain is assumed to have some cost
f resistance, s, deﬁned such that the basic reproductive num-
er of the resistant strain is RR0 = R00(1 − s). We  assume the same
ost applies to the resistant strain whether or not drug is used.
revious multi-strain population dynamic models, e.g. Bonhoeffer
nd Nowak (1997), Ribeiro and Bonhoeffer (2000), Gadhamsetty
nd Dixit (2010), Rong et al. (2010), Adiwijaya et al. (2010), have
ypically assumed costs through one particular trait. This assump-
ion may  be realistic; for instance, there is biological evidence
o suggest that the cost of protease inhibitor resistance in HCV
hould be borne by the virion production rate (Adiwijaya et al.,
010). Furthermore, for HIV, known drug resistance mutations
ypically occur in the drug target (Goldberg et al., 2012; Johnson
t al., 2011), suggesting that the cost is also likely to be incurred
hrough the function of the target protein. However, one could
rgue that general metabolic costs, as well as pleiotropic effects
e.g. a mutation in the HIV envelope gene making virions more
isible to the immune system), could give rise to costs via other
raits. Indeed, there is currently limited understanding of the exact
echanisms of ﬁtness costs. Experimental ﬁtness assays to date
enerally do not allow one to pinpoint the affected trait or mea-
ure genetic differences in more than one trait (Rong et al., 2007;
adhamsetty and Dixit, 2010). This motivates us to consider a more
eneral model where the resistant strain may  differ in any viral
rait (ˇ, a, k, or c). For illustration in numerical results, we  will
ake a cost in only one trait at a time, such that ˇR = (1 − s)ˇS,
R = (1 − s)kS, aR = aS/(1 − s), or cR = cS/(1 − s). However, the model
nd analysis still apply when the cost manifests itself through
ultiple traits, in which case the extent of the cost to each indi-
idual trait must be speciﬁed. In principle, s may  take on any value
etween 0 and 1, and there is evidence that the cost of resis-
ance indeed varies widely (see Supplementary Material). Here we
how results under treatment with s chosen such that RR0 > 1; oth-
rwise, the resistant strain could not persist in the presence of
rug.
For analytical approaches, the model can be simpliﬁed by mak-
ng two assumptions that are widely used in the literature and
an be justiﬁed for parameter estimates in diseases of interest;
ee Supplementary Material for details. Firstly, we assume that the
oss rate of virions through infection is negligible relative to clear-
nce, which is valid when the burst size (k/a) is considerably larger
han the basic reproductive number (R00). Secondly, we  assume that
he dynamics of free virions are much faster than those of infected
ells, which is valid when virion production (k) and clearance (c)idemics 4 (2012) 187–202 189
rates are large (Lloyd, 2001). We  then have the quasi-equilibrium
relationships:
vS ≈
kS
cS
(1 − P)(1 − uP)yS +
kR
cS
uPyR
vR ≈
kS
cR
(1 − P)uPyS +
kR
cR
(1 − uP)yR (2)
and  the following approximation of system 1:
x˙  =  − dx −
(
ˇSkS
cS
(1 − I)(1 − P)(1 − uP) +
ˇRkS
cR
(1 − P)uP
)
xyS −
(
ˇSkR
cS
(1 − I)uP +
ˇRkR
cR
(1 − uP)
)
xyR (3a)
y˙S =
(
ˇSkS
cS
(1 − I)(1 − P)(1 − uI)(1 − uP) +
ˇRkS
cR
(1 − P)uIuP
)
xyS+
(
ˇSkR
cS
(1−I)(1−uI)uP +
ˇRkR
cR
uI(1−uP)
)
xyR−aSyS (3b)
y˙R =
(
ˇSkS
cS
(1 − I)(1 − P)uI(1 − uP) +
ˇRkS
cR
(1 − P)(1 − uI)uP
)
xyS+
(
ˇSkR
cS
(1−I)uIuP+
ˇRkR
cR
(1 − uI)(1−uP)
)
xyR−aRyR (3c)
In the majority of this manuscript we focus on the correspond-
ing stochastic version of the model, which is a continuous-time
Markov process with transition rates according to the rates of the
ODE model. (Note however that the given system of ODEs does not
exactly describe the means in this stochastic model, due to corre-
lations between population sizes: see Heffernan and Wahl (2005).)
We use the simpliﬁed system 3 to derive analytical approximations.
Importantly, however, we  conduct simulations of the full system 1,
which provides a check that the results are robust to the model sim-
pliﬁcations. Figures use a standard set of parameter values unless
otherwise speciﬁed. Details of simulation methods and parameter
values are provided in Supplementary Material.
Results
Life cycle effects on the mutation-selection balance
Before treatment begins, the resistant strain has a selective dis-
advantage relative to the sensitive strain, and is thus observed
in a mutation-selection balance. In the deterministic model, the
observed mutant frequency depends on features of the life cycle.
Taking  I = P = 0 to represent the absence of drug, we  can solve
for the approximate pre-treatment infected equilibrium (x∗, y∗S, y
∗
R)
in the simpliﬁed ODE model:
x∗ = aScS
ˇSkS
= x0
R00
(4a)
y∗S =

aS
− dcS
ˇSkS
(4b)y∗R =
(aS/aR)(uI + (ˇRcS)/(ˇScR)uP)
s
y∗S (4c)
where x0 = /d is the uninfected equilibrium level of target cells.
(See Supplementary Material for derivation.) In particular, we can
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onsider the special cases where the cost manifests itself through
 single trait:
y∗R
y∗S
=
⎧⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎩
uI + (1 − s)uP
s
, for a cost through  ˇ or c
(1  − s)(uI + uP)
s
,  for a cost through a
uI + uP
s
,  for a cost through k
(5)
ote that these expressions do not always coincide with the clas-
ical mutation-selection balance of u/s (with u ≡ uI + uP the total
utation rate), although in all cases they do approach this ratio
or small s. Rather, the frequencies depend on the life history trait
hrough which the cost manifests itself and the step of the life cycle
t which mutation acts, with strongest effect when the cost (s) is
arge. To gain an intuitive understanding, consider the limiting case
f large cost (s → 1, such that RR0 → 0). This means that a mutant
s unable to complete a full life cycle. However, the observed fre-
uency of mutants depends on the particular step(s) of the life cycle
ffected. We  can distinguish between costs to persistence and costs
o productivity. By “persistence”, we mean any trait that affects the
bility of a mutant to survive from de novo production through to
nd including the infected cell stage; that is, a in any case, and addi-
ionally ˇ and c if the mutant ﬁrst arises in virion production. By
productivity”, we mean any trait that affects the rate at which a
utant infected cell generates new infected cells: that is, k in any
ase, and additionally  ˇ and c if the mutant ﬁrst arises in cell infec-
ion. If a mutant is defective in persistence, in the limit it will die so
uickly that it will never be present (as an infected cell). However,
f a mutant is defective only in productivity, it will still be present
t non-zero frequency, since it is continually generated by de novo
utation from the wild type and has no deﬁciency in survival once
enerated.
We also observe that the mutant frequency is not necessarily
he same among free virions as it is among infected cells, although
nterchanging the corresponding parameters for mutation, produc-
ion and loss rates gives parallel results (Supplementary Material).
he effects of  ˇ and c are identical in our model framework, because
hese are parameters related to free virions, wrapped into one step
y the quasi-equilibrium approximation. The grouping of parame-
er effects switches if we look at the frequency among free virions
Supplementary Material). If uP = 0 (resp. uI = 0), the differences
mong parameters further collapse, since there is no possibility of
 mutant ﬁrst arising in the free virion (resp. infected cell) stage.
istribution  of mutant population size
In the pre-treatment phase, a mutant strain with a cost will be
are, maintained only by continual mutation from the wild type,
nd thus subject to signiﬁcant stochasticity. The population size is
ot well captured by its average or deterministic prediction alone,
ut can be better described through its entire probabilistic distri-
ution. At “equilibrium”, i.e. once the population size distributions
ave stabilized, this distribution can be well approximated by the
teady state of a birth-death-immigration (BDI) process with con-
tant parameters.
Speciﬁcally, the mutant population (yR) follows a BDI process
here “birth” represents replication of a mutant infected cell, by
enerating infection in another target cell; “death” is death of a
utant infected cell; and “immigration” represents de novo muta-
ion from the wild type. The key to this approximation is to suppose
hat target cells and wild type infected cells (x and yS, respec-
ively) are effectively at their deterministic equilibrium population
izes, yielding constant rates for each of the aforementioned events.
lthough the populations do show stochastic ﬂuctuations, theseidemics 4 (2012) 187–202
variations  are small relative to the means, and have minimal effect
on the mutant infected cell population.
In Supplementary Material, we identify the rates of these events
and apply standard results (Kendall, 1949) to obtain the following
probability generating function (PGF) for the distribution of mutant
population size at the pre-treatment equilibrium:
 (z) =
(
s
1 − (1 − s)z
)(aS/(aR(1−s)))(uI+(ˇRcS)/(ˇScR)uP )y∗S
(6)
(The  variable z here is a placeholder in the generating function, see
e.g. Wilf (1994); it is not associated with a particular quantity in the
model.) The function is particularly simple for costs through single
traits:
 (z) =
⎧⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎩
(
s
1 − (1 − s)z
)(uI/(1−s)+uP )y∗S
, for a cost through  ˇ or c
(
s
1 − (1 − s)z
)(uI+uP )y∗S
, for a cost through a
(
s
1 − (1 − s)z
)((uI+uP )/(1−s))y∗S
, for a cost through k
(7)
Hence the distribution of the number of pre-existing mutants
depends on the wild type infected cell population size, as well as
the probability of mutation and the cost of the mutation at each
step of the life cycle. It does not, however, depend on the precise
parameter values associated with the virus, so long as we  know the
costs relative to the wild type.
In a more specialized model, the same approach has previously
been used to approximate the distribution of mutant population
size at equilibrium (Ribeiro, 1999). However, the method was used
only to ﬁnd the probability of having zero mutants, the mean and
the variance of the distribution. Here we investigate the entire dis-
tribution, as well as generalizing to various viral life cycles.
The  analytical approximation generally shows an excellent ﬁt to
simulation results: see Fig. 1. The left column shows costs through
ˇ; the right column, through a. Substantial differences arise only
when s is sufﬁciently large. Speciﬁcally, when comparing two costly
traits with a given mutational step, the proportional reduction in
the mean number of mutants is either 0 or s (see Eq. (5)). Corre-
spondingly, life cycle differences have only a small effect on the
entire distribution when s is small (top row). However, when s is
larger, the distributions may  differ substantially, as illustrated in
the middle and bottom rows. Comparing left to right panels, we
see how cost via different traits can affect the number of mutants
present, while comparing middle to bottom panels, we  see the
impact of mutation mechanism. Depending on the costly trait, the
step at which mutations occur may  or may  not affect the distribu-
tion, and vice versa. Overall, these results show the potentially large
effect of life cycle when costs are not small, while highlighting the
point that it is the interaction between mutational step and costly
step that matters.
As  s → 0, all parameters collapse to the wild-type values. How-
ever, it is not surprising that the dependence on the particular
mechanism of the cost increases with the magnitude of the cost.
We can consider the limiting case analytically by taking the limit
as s → 1 in the PGF (Eq. (6)). It turns out that for any single-
trait cost, the limiting distribution is Poisson, with mean given
by the deterministic y∗R evaluated at s = 1. Thus, the results agree
with the intuition developed in Section “Life cycle effects on the
mutation-selection balance”: in particular, for mutants defective
in persistence, the distribution approaches a point mass at zero,
while for mutants defective in productivity, the distribution has a
non-zero mean. In a stochastic setting, we can understand the form
of the limiting distribution by noting that if a mutant cannot com-
plete its replication cycle, every mutant present must be generated
de novo from the wild type. These events occur according to a pure
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Fig. 1. The distribution of the number of mutant infected cells (yR) at pre-treatment equilibrium, for various life cycles and costs. Grey bars show the frequency (probability)
of a given population size among 5000 simulations, and points show the BDI approximation of the probability. Top two rows: mutation upon infection (uI > 0); bottom row:
mutation upon virion production (uP > 0). Left column: cost through ˇ; right column: cost through a. Costs are s = 0.1 (top row) or s = 0.9 (bottom two rows). In the top row,
r  total 
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a
iesults are grouped by 10’s for easier visualization; the vertical axis then shows the
oisson process with immigration rate I, and the mean number of
utant infected cells present is then given by the immigration rate
imes the average lifespan of a mutant infected cell (I × 1/aR). In
eneral, for s < 1, the distribution of mutant population size is not
imply Poisson, since de novo mutation (immigration) events are
ompounded by mutant self-replication. Nonetheless, it is possi-
le through the BDI steady state to capture the full distribution
nalytically with high accuracy.
arget  cell rebound and stochastic extinctions during treatmentAlthough the mutant strain is assumed to have ﬁtness RR0 > 1,
nd likely a substantial ﬁtness advantage over the wild type dur-
ng treatment, there is no guarantee that it will escape stochasticprobability of being within this range.
extinction  when initially rare. That is, the persistence of mutants –
not only their appearance – is a potentially signiﬁcant component in
evaluating risks, but one that has previously been considered only
to a limited extent (Ribeiro, 1999; Ribeiro and Bonhoeffer, 2000;
Roberts and Ribeiro, 2001; Pennings, 2012).
The chance that a mutant persists critically depends on the avail-
ability of target cells for new infections. When treatment begins,
target cells are at the equilibrium set by the previously dominant
wild type; under the assumption that the mutant carries a cost, this
level is necessarily too low to support self-sustained growth of the
mutant population. However, once a (sufﬁciently effective) drug
blocks wild type infections, the target cell population gradually
rebounds from pre-treatment levels towards the uninfected equi-
librium, conferring an ever-increasing infection rate on the mutant
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Fig. 2. The probability of extinction of a single mutant’s lineage during the treatment phase. The solid line shows the analytical approximation given by Eq. (8) and the points
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“how simulation results with various drug efﬁcacies (black:  = 1, grey:  = 0.8, unﬁl
f resistance is taken through infectivity (ˇ). Left: A single mutant is introduced at t
reatment starts (t = 0) and probability of extinction is plotted as a function of cost, 
opulation. This implies that mutants arising later are predicted to
ave a better chance at escaping extinction, and in particular, any
utant that arises before the target cell population has rebounded
o the infected equilibrium level set by the mutant strain must per-
ist until this point in order to have a non-zero chance at escaping
xtinction.
We have derived an analytical approximation for the probabil-
ty that a single mutant existing at a given time after treatment
nitiation escapes early stochastic extinction and thus has long-
erm descendants. Details can be found in Supplementary Material.
rieﬂy, we model the population descending from one progenitor
ith a time-inhomogeneous birth-death process. Births (i.e. new
nfections) and deaths occur very similarly to the pre-treatment
hase; the key difference is that the target cell population (and
ence the birth rate) is now time-dependent. We  ﬁnd that a mutant
xisting at time t after treatment starts ultimately has no surviving
escendants with probability:
ext(t) = 1 − (1 + R exp(g1(Re−dt, R00, s))(g1(Re−dt, R00, s))
−g2(R,R00,s)
· (g2(R, R00, s), 0, g1(Re−dt, R00, s)))−1 (8)
here  R = aR/d represents the relative infected cell death rate
as per the deﬁnition in (Ribeiro, 1999; Ribeiro and Bonhoeffer,
000)), and we deﬁne for convenience the functions g1( , R0,
) = (R0 − 1)(1 − ) and g2( , R0, ) = (R0(1 − ) − 1). Furthermore,
(z,  c1, c2) :=
∫ c2
c1
xz−1e−xdx is the generalized incomplete gamma
unction.
Importantly, this probability is a function of the time at which
he mutant arises. This time is scaled relative to the uninfected cell
eath rate, d, which deﬁnes the rate at which target cells rebound.
ince target cell availability is increasing, the total birth rate is also
ncreasing and hence the chance of extinction is decreasing over
ime, as illustrated in Fig. 2 (left). Eq. (8) shows that the proba-
ility of extinction depends on three further key parameters: the
elective disadvantage, s; the death rate of mutant infected cells,
elative to uninfected cells, R; and the baseline reproductive num-
er, R00. As expected, the probability of extinction increases with
, as shown in Fig. 2 (right). The intuition that the probability of
xtinction increases with infected cell death rate is also supported
umerically. This means that a mutant with a cost through higher
eath rate (a) will always have a smaller chance of escaping extinc-
ion than a mutant with the same ﬁtness cost but through lower
birth” rate (i.e. through any parameter affecting the rate at which= 0.55). Drug is assumed to act by blocking cell infection (I ≡ ; P = 0) and the cost
fter treatment starts, with a cost of s = 0.3. Right: A single mutant exists at the time
infected  cells are generated: ˇ, k, or c). Finally, it can be shown
that the “birth” rate of infected cells is increasing with the baseline
reproductive number R00, and hence the probability of extinction
decreases with R00. That is, the increased per-target-cell replicative
capacity outweighs the greater pre-treatment depletion of target
cells. The drug efﬁcacy  does not appear in the analytical expres-
sion for the probability of extinction, since we  assume that target
cells rebound as if no further infections occur. However, we expect
the approximation to be an underestimate of extinction for lower
values of , since a drug that allows more ongoing replication of
the wild type will lead to more competition for target cells than
predicted. Nonetheless, simulation results using various drug efﬁ-
cacies (points in Fig. 2) show that the approximation (solid line) is
fairly robust to this assumption.
Contributions  of pre-existence and rescue
As described in the Introduction, there has been considerable
interest in comparing the contributions to the emergence of resis-
tance made by “pre-existing” versus “rescue” mutants. The term
pre-existence is used widely in the literature, e.g. Bonhoeffer and
Nowak (1997), Ribeiro and Bonhoeffer (2000), Rong et al. (2010),
and refers to mutants arising de novo before treatment begins and
present when treatment starts. Rescue mutants are deﬁned here as
mutants that are generated de novo after treatment starts and that
have long-term descendants. The term rescue is borrowed from the
conservation biology and population genetics literature (Orr and
Unckless, 2008; Bell and Gonzalez, 2009) and there refers to the
outgrowth of any mutant, while here we reserve the term only for
mutants that arise during the treatment phase.
Our general approach to calculating the probability of emer-
gence of resistance (i.e. viral population survival under treatment)
is ﬁrst to consider how mutants arise, thus determining the num-
ber and timing of incipient lineages. The viral population fails to
persist if and only if all these lineages die out; we can approximate
this probability by treating each lineage independently. We  apply
this approach separately to mutants arising either before or after
treatment initiation, in order to isolate each contribution.Pre-existence
Assuming treatment begins after the system has equilibrated,
the total number of pre-existing mutants, N, has a distribu-
tion approximated by the birth-death-immigration steady state
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P9) and the points show the proportion of simulations (1000 per point) surviving
o  the end of the run (various drug efﬁcacies – black: I = 1, grey: I = 0.8; unﬁlled:
I = 0.55; all with P = 0).
istribution, with PGF  (z) given by Eq. (6). Thus, the probability
f survival due to pre-existence, under independence, is:
pre = 1 −
∞∑
n=0
Pr(N = n)pext(0)n = 1 − (pext(0)) (9)
his  probability depends on two components: the number of
utants pre-existing (investigated in Section “Distribution of
utant population size”) and each one’s chance of survival once
reatment starts (Section “Target cell rebound and stochastic
xtinctions during treatment”). The ﬁrst component is affected by
ost of resistance, mutation probabilities, and pre-treatment wild
ype infected cell population size; and the second component, by
elative infected cell death rate, baseline reproductive number, and
gain cost.
Fig.  3 illustrates the dual disadvantage incurred by the cost of
esistance: (1) there are fewer mutants to begin with and (2) each
utant is less likely to survive, due to inefﬁcient replication, which
equires a greater extent of target cell rebound to sustain growth.
hus, as s increases, the probability of survival drops off sharply.
he analytical approximation again shows very good agreement to
imulation results and robustness to varying drug efﬁcacy.
escue
We  model the appearance of rescue mutants with a time-
nhomogeneous Poisson process. The rate at which mutants arise
uring treatment depends on the level of residual replication of
he wild type and the probability of mutation. The total rate of de
ovo mutation thus declines with the wild type population over
ime. Furthermore, a mutant is only counted as a rescue mutant if
ts lineage ultimately escapes extinction. Thus the rate of appear-
nce is weighted by the time-dependent probability of escaping
xtinction considered in Section “Target cell rebound and stochas-
ic extinctions during treatment”. These factors together give the
ate of events in the Poisson process over time. Applying results for
ime-inhomogeneous Poisson processes (Parzen, 1999), we have
he following expression for the probability that rescue occurs:
resc = 1 − e−
∫ ∞
0
(1/d)(t/d)dt
(10)idemics 4 (2012) 187–202 193
where (t) is the rate of appearance of rescue mutants (i.e. those
that ultimately have surviving descendants) at time t after treat-
ment begins:
(t) = dy∗SR00S(1 − P )
(
(1 − I)uI + ˇRcS
ˇScR
uP
)
(1 − (1 − 1/R00)e−dt)
× exp(g1(S, R00, )(e−dt − 1) + g2(S, R00, )dt)(1 − pext(t)) (11)
(for derivation see Supplementary Material). Here
 : =1 − (1 − P)(1 − I), S : = aS/d, and the functions g1 and g2
are deﬁned as for Eq. (8).
The total contribution of rescue mutation depends on the com-
bined effects of the de novo mutant production rate and the chance
that each mutant survives. The impacts of drug efﬁcacies and muta-
tion rates come in only through production; in particular, Presc can
be made arbitrarily low by taking sufﬁciently low mutation rate
or, for certain life cycle and drug combinations (see below), suf-
ﬁciently high drug efﬁcacy. Note that the expression here for the
rate of mutant appearance is not always independent of the cost
of resistance; this is because we  track the appearance of infected
cells, and mutants that arise at the virion production stage must
ﬁrst avoid clearance and infect a target cell in order to be counted.
Thus the “conversion factor” ˇRcS/ˇScR appears for mutants arising
at the virion stage (via uP). However, in a biological sense, properties
of the mutant itself, including cost s and relative resistant infected
cell death rate R, only affect its survival and not its appearance.
Uninfected cell death rate, d, does not affect Presc separately from
its contributions to R00 and the relative infected cell death rates.
Mathematically, this is because d only appears in the product dt,
and we integrate over all time to obtain the probability of eventual
extinction. Thus, d gives an intrinsic rescaling of time, affecting the
speed of the dynamics but not the eventual outcome.
The quasi-equilibrium proportionality between free virus and
infected cells is reached only after a full replication cycle under
treatment. This necessitates a small correction to Presc account-
ing for the contribution of new infections by pre-existing sensitive
free virions. Adding the resistant infected cells produced by these
sensitive virions yields the modiﬁed approximation:
P ′resc = 1 − e
−m1(1−pext(0))−
∫ ∞
0
(1/d)(t/d)dt
(12)
where m1, the approximate expected number of mutant infected
cells produced in the ﬁrst cycle, is given by
m1 =
(1 − I)uIy∗S
cS/aS
(see Supplementary Material for details).
Fig. 4 illustrates the dependence of the probability of rescue on
cost of resistance and drug efﬁcacy. We  here use an HIV-like life
cycle (mutations and cost at cell infection) with either a reverse
transcriptase inhibitor or a protease inhibitor (drug acting at cell
infection or virion production, respectively). The results are com-
pared to three analytical approximations: our Presc and P ′resc derived
above, and the probability of producing at least one de novo mutant
during treatment (excluding the ﬁrst cycle of infection by free viri-
ons), without taking into account stochastic extinctions. The latter
approximation is comparable to that used in some previous studies
(Ribeiro, 1999; Ribeiro and Bonhoeffer, 2000). Simulation results
generally align best with P ′resc, although the deviation from Presc
may  be small. The probability of producing a mutant is indepen-
dent of its cost s (for this life cycle). However, a mutant with a
higher cost of resistance is less likely to escape extinction, such that
the probability of survival declines with s, as shown in the top two
rows. Thus, failing to account for stochastic extinctions yields the
largest inaccuracies when the cost of resistance is high. On the other
hand, to a good approximation, the drug efﬁcacy plays no role in the
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Fig. 4. The total probability of survival due to rescue mutation. The lines show analytical approximations – solid: P ′resc given by Eq. (12); dotted: Presc given by Eq. (10)
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locks cell infection (I ≡ ); on the right, the drug blocks virion production (P ≡ ).
ow: probabilities as a function of s, for  = 0.95. Bottom row: probabilities as a func
ersistence of a resistant mutant once produced. However, the
igher the efﬁcacy, the less residual replication of the sensitive
train, and thus the fewer de novo mutations occur. Therefore, both
he probability of production and the total probability of survival
ecline with  (bottom row).
ife cycle effects on pre-existence and rescue
A key point of interest is to investigate the impact of life
ycle on the emergence of drug resistance. To this end, we
onsider the four life cycles illustrated in Fig. 5, taking each
ossible combination of mutation step and drug action step in
ur model framework. That is, we assume mutation occurs with
robability u at either cell infection (uI ≡ u) or virion produc-
ion (uP ≡ u), and that the drug acts with efﬁcacy  at either cell
nfection (I ≡ ) or virion production (P ≡ ). Of course, muta-
ion or drug action could also occur at both steps, but we  can
iew these four cases as the extremes. We  suppose a cost may
rise at any single step of the life cycle. At ﬁrst, this appearsion at cell infection (uI > 0, uP = 0) and a cost via infectivity (ˇ). On the left, the drug
w: probabilities as a function of cost of resistance s, for drug efﬁcacy  = 0.8. Middle
f , for s = 0.1 (black) or s = 0.4 (grey).
to  give rise to an inconveniently large number of possibilities
to consider. However, through our analytical understanding of the
probability of emergence, it turns out that the number of distinct
cases collapses considerably.
First  consider Ppre, which depends on the number of pre-existing
mutants (captured by  (z)) and each one’s chance of stochastic
extinction (captured by pext(0)). The distribution of pre-existing
population size depends on mechanisms of cost and mutation, but
not on the drug. This distribution separates into two  distinct cases:
(1) when mutation occurs at cell infection and cost is via ˇ, c, or
k, or mutation occurs at virion production and cost is via k and (2)
when mutation occurs at cell infection and cost is via a, or mutation
occurs at virion production and cost is via ˇ, c, or a. In particular,
the mean of the distribution is higher in the ﬁrst case. The chance
of extinction depends on neither mechanism of mutation nor drug,
but does depend on the mechanism of cost. Recall, however, that
pext(t) is identical for ˇ, c, or k costs, and higher for a cost via a. In
summary, we see that Ppre collapses into three cases, as illustrated
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n Supplementary Fig. 1. Note that, in the case of mutation at cell
nfection, increased infected cell death confers the dual disadvan-
age of a smaller pre-existing population size and a lower chance
f escaping stochastic extinction.
Next we consider P ′resc, which can be characterized by the rate
f rescue mutations, (t), and the expected number of “ﬁrst round”
utants, m1. We can write
(t)  = C(t)(1 − P)
(
(1 − I)uI +
ˇRcS
ˇScR
uP
)
(1 − pext(t))
here the factor C(t) := dy∗SR00S(1 − (1 − 1/R00)e−dt) exp((e−dt −
)g1(S, R00, ) + g2(S, R00, )dt), declining over time with the wild
ype population, does not vary according to life cycle. Similarly,
1 = A(1 −I)uI where A := y∗S/(cS/aS) is independent of life cycle.
hus, the components of P ′resc in the various life cycles can be sum-
arized as in Table 1.
Consider ﬁrst the interaction between the mechanisms of
utation and cost. If mutation occurs at cell infection, any cost
echanism affecting the production rate of new infected cells (ˇ,
, or k) is equivalent, while a cost affecting the loss rate of infected
ells (a) yields a lower probability of survival. If mutation occurs at
irion production, the situation is more complicated. Mutants ﬁrst
ppear at the free virion stage, so a cost via c or ˇ will reduce the
hance that a mutant infected cell is subsequently produced. On
he other hand, a cost via a will reduce the chance that a mutant
nfected cell has long-term descendants. Thus, P ′resc is highest if the
ost is incurred via k.Next we consider the interaction between the mechanisms of
utation and drug action. We  refer to scenarios where the drug
locks the step at which mutation occurs as “synchronous”. In these
ases, a perfectly effective drug with  = 1 leads to P ′resc = 0, since
able 1
ummary of rescue rates in the various life cycles. The factors C(t) and A, deﬁned in the m
Drug at cell inf. 
Mut. at cell inf., (t)  = C(t)(1 − )u(1 − pext(t)) 
Any  cost mech. m1 = A(1 − )u 
Mut.  at virion prod., (t) = C(t)u(1 − pext(t)) 
k  or a cost m1 = 0 
Mut.  at virion prod., (t) = C(t)(1 − s)u(1 −pext(t))
ˇ  or c cost m1 = 0 te production, and crosses indicate inhibition of this production by the drug.
there  is no possibility to generate de novo mutants. On the other
hand, if the drug effect and mutation step are “asynchronous”, the
drug is not directly blocking the generation of resistant mutants. In
these cases,  = 1 does not lead to P ′resc = 0 because the pre-existing
sensitive populations can still generate resistant mutants in the
replication step uninhibited by drug. The difference between these
two scenarios is most apparent when drug efﬁcacy is high. A partic-
ularly high probability of rescue arises when mutations occur upon
virion production and the drug blocks cell infection, since mutants
are directly generated by relatively long-lived infected cells rather
than short-lived free virions. Supplementary Fig. 2 illustrates the
possible distinct cases.
When  is rescue important?
We  now have substantial analytical understanding of Ppre and
P ′resc individually; however, it is not obvious how these quantities
compare. Having demonstrated the accuracy of our approximations
for these probabilities (preceding sections and Supplementary
Material), we now investigate parameter effects using only ana-
lytical results. Since the question of which source contributes more
to the emergence of resistance has been the topic of earlier studies,
it is useful to delineate exactly how our work differs, particularly
from previous work on an intra-host viral dynamics model taken
in the single-locus case (Ribeiro and Bonhoeffer, 2000). To this end,
there are two key differences in the model itself: we generalize
across life cycles, and we  take into account stochastic extinctions
of rare mutants during the treatment phase. Moreover, there is
a question of how to measure contributions of pre-existence and
rescue.
Relative contributions have previously been quantiﬁed using
expected numbers of mutants from each phase: speciﬁcally,
the ratio E[# mutants during treatment]/E[# pre-ex. mutants],
ain text, do not depend on life cycle.
Drug at virion prod.
(t) = C(t)(1 − )u(1 − pext(t))
m1 = Au
(t) = C(t)(1 − )u(1 − pext(t))
m1 = 0
(t) = C(t)(1 − s)(1 − )u(1 − pext(t))
m1 = 0
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Fig. 6. Effect of drug efﬁcacy  on the relative importance of rescue, as measured by PR\P . Darker shading on the density plots corresponds to a larger value of PR\P (white = 0,
black = 1), and contour lines (red) indicate values of 0.1–0.9 in increments of 0.2. Top panels: Life Cycle A; bottom panels: Life Cycle B. The parameters R00 = 2 and  = 10 are
ﬁ alized
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 = 0.55, 0.7 and 0.9, from left to right panels. (For interpretation of the references t
enoted 1 (Ribeiro and Bonhoeffer, 2000). For direct comparison,
e can deﬁne the corresponding ratio ˜1, which is valid for more
eneral life cycles but otherwise differs only by taking stochastic
xtinction into account and by the (typically small) correction
ade for ﬁrst-round replication of free virions (m1). An analytical
xpression for ˜1, which elucidates parameter dependencies, is
rovided in Supplementary Material. First, ˜1 depends on the
ife cycle-speciﬁc parameters s, , and u. Second, it depends on
he composite parameters S, R00 and cS/aS (which affects only
he correction factor m1). The population size y∗S cancels out.
urthermore, if mutation occurs in only one step (uP = 0 or uI = 0),
he non-zero mutation rate also cancels, as found previously for
 particular life cycle (Ribeiro and Bonhoeffer, 2000). We also
nd that taking survival of mutant lineages into account always
ncreases this measure of the relative contribution of mutants
rising after treatment begins (see Supplementary Material). Intu-
tively, this is because mutants arising de novo during treatment
ncounter a higher level of target cells and thus a lower probability
f extinction.
Although the above analysis is useful for direct comparison with
revious work, we argue that a more relevant measure of con-
ributions is the probability of having at least one survivor, rather
han the expected number of survivors. The long-term outcome
nder treatment is the same regardless of how many founders
f resistant lineages there are, so long as there is at least one. as a proportion of the maximum cost allowed, smax = 1 − 1/R00. We select values of
ur in this ﬁgure legend, the reader is referred to the web version of the article.)
Furthermore, since pre-existence chronologically occurs ﬁrst, we
re-frame the question of relative contributions to ask, “When does
rescue make an important contribution to the emergence of resis-
tance?” That is, if pre-existence is virtually guaranteed to result in
emergence, we have little interest in how many more rescue muta-
tions subsequently occur. However in any case, for rescue to be
signiﬁcant, its probability must be sufﬁciently high. We  therefore
use the measure:
PR\P := (1 − Ppre)P ′resc
which is, to a good approximation, the probability that no pre-
existing mutants survive but at least one rescue mutant survives.
This measure reﬂects when rescue is important in changing the
outcome of a treated infection.
The  measure PR\P depends on the life cycle-speciﬁc parameters
s,  and u · y∗S and the composite parameters S, R00 and cS/aS. In con-
trast to ˜1, the parameters y∗S and uI or uP no longer cancel out, but
only ever appear as products (uIy∗S and uPy
∗
S) representing the total
mutational inﬂux. This is not surprising, since the population of
sensitive infected cells is homogeneous and thus it does not matter
from which particular cell a de novo mutant arises.
Since cS/aS typically has a minor effect (only via m1), we focus
on the effects of s, , S, R00, and u (with the understanding that y
∗
S
has an equivalent effect). For illustration, we  select two life cycles,
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Fig. 7. Parameter effects on the relative importance of rescue, as measured by PR\P , in Life Cycle A. Shading and contours are the same as in Fig. 6. Drug efﬁcacy  is ﬁxed for
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0 under treatment is an intermediate value of 0.6, while mutati
aximum possible cost, smax = 1 − 1/R00, allowed for a given R00. Relative infected c
own each column over values (top to bottom) 2, 6, and 10.
hich we found in the previous section to have highly divergent
ehaviour in P ′resc. Both have mutation at virion production and a
ost through k, but Life Cycle A (synchronous) has the drug acting at
irion production, while Life Cycle B (asynchronous) has the drug
cting at cell infection. These two life cycles are chosen because they
iffer only in rate of rescue mutation (t) (both having m1 = 0 and
dentical Ppre) and thus allow a more straightforward comparison.
We can visualize parameter effects through density plots of PR\P
Figs. 6–8 ), here illustrated in the (u, s) plane. Darker shading
epresents higher values of PR\P, that is, greater importance of res-
ue. Two unequivocal effects are apparent. Firstly, asynchronicity
etween drug action and mutation always results in a larger con-
ribution of rescue, as we would expect from the previous section.
isually, this is evident from a comparison of the top and bottom
anels in Fig. 6, or of Figs. 7 and 8, showing corresponding results for
ife Cycles A and B respectively. Secondly, the impact of drug efﬁ-
acy  is also obvious: increasing  always decreases P ′resc without
hanging Ppre, and thus rescue is more important at low  (Fig. 6).e u and cost s vary as indicated on the axes. s is normalized as a proportion of the
ath rate  varies across each row over values (left to right) 2, 10, and 25. R00 varies
The  remaining parameter effects are less clear. In particular, R00
affects the number and timing of de novo mutants during treat-
ment in inconsistent directions, and the sensitivity of pext(t) to R00
across time is not straightforward. This feeds through to compli-
cated effects on PR\P. We  thus show plots across various R00 values
only to demonstrate robustness of other effects, without focussing
on the impact of R00 itself.
The other key parameters (u, s, and ) each affect both Ppre and
P′resc in the same direction, yielding counteracting effects on PR\P. As
a result, varying these parameters can have non-monotonic effects
on PR\P. For instance, PR\P will be zero at both very low mutation
rates (such that Ppre ≈ P ′resc ≈ 0) and very high mutation rates (such
that Ppre ≈ P ′resc ≈ 1), but generally non-zero in between. That is, as
Figs. 7 and 8 indicate, rescue can be signiﬁcant at some intermediate
range of u.
The  role of  is more complicated. The probability of sur-
vival decreases at all times as  increases, but this dependence is
stronger at earlier times. (Note that the asymptotic value of pext(t) is
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ettings the same as in Figure 7.
ndependent of  .) This incurs a relative disadvantage to mutants
rising earlier, particularly those pre-existing. On the other hand,
hile increasing  (with other parameters ﬁxed) does not affect
he number of pre-existing mutants, it reduces the number of
utants produced under treatment and tends to push this pro-
uction earlier, incurring a relative disadvantage to rescue. Overall,
hen, increasing  may  either favour or disfavour rescue, depend-
ng on other parameter settings. Although increasing  decreases
R\P in the parameter region of Figs. 7 and 8, non-monotonic effects
an be observed in other regions, as illustrated by density plots in
he (u, ) plane (Supplementary Figs. 3 and 4).
An overall study of the plots in Figs. 7 and 8, as well as
upplementary Figs. 3 and 4, suggests that rescue tends to make the
ost signiﬁcant contribution when the cost of resistance is fairly
igh. This can be understood through the aforementioned dual dis-
dvantage of cost incurred by pre-existing mutants. Whereas s does
ot affect the appearance of de novo mutants (for the life cycles
nder consideration), it decreases the number of pre-existing
utants, which have already faced selection in the pre-treatment
nvironment. Furthermore, costly mutants face the greatestfe Cycle B. Shading and contours are the same as in Figs. 6 and 7, with parameter
extinction risk early in treatment, when target cell levels are low-
est. Nonetheless, PR\P must necessarily drop off to zero at extremely
high costs, for which survival is not possible (RR0 drops below 1). The
aforementioned factors suggest that, as s increases, it is Ppre that
drops off before P ′resc, allowing an interval of relatively high cost at
which rescue can make the major contribution to survival.
It  is apparent that the key parameters show complex interac-
tion effects. That is, for no parameter besides  can we  identify a
directional effect on PR\P that holds independently of other param-
eter settings. It is thus important to keep in mind that, although we
have investigated the role of each parameter separately, there are
likely to be correlations between their true values. For instance,
relative infected cell death rate () cannot increase indeﬁnitely
without reducing R00. Certain interaction effects can be delineated.
For instance, as u increases, the value of s maximizing PR\P also
increases (Figs. 7 and 8). This is because a larger number of mutants
implies that both Ppre and P ′resc remain close to one over a larger
range of s. That is, when the mutational inﬂux is high, rescue only
makes a difference for very costly mutants, but when mutations are
rare, rescue can be signiﬁcant even for lower cost mutants.
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Fig. 9. Histogram of time on treatment until total viral load reaches the detection
limit  of 105. The distribution is derived from 390 simulation runs showing viral
rebound  in each case. Hatched: pre-existing mutants; grey: rescue mutants. We see
the overlap in the darker regions. Simulations were performed for a life cycle with
mutation at cell infection, cost at infectivity (ˇ) of s = 0.3, and drug blocking cell infec-H.K. Alexander, S. Bonhoeff
The increased complexity of parameter effects on the contribu-
ion of rescue in our model, compared to previous work (Ribeiro
nd Bonhoeffer, 2000), can in part be attributed to the measure of
ontribution we use. Since probabilities (unlike expected numbers)
re constrained between 0 and 1, certain parameter effects saturate.
hat is, once there are so many mutants that survival is extremely
ikely (or so few that survival is extremely unlikely), pushing
arameters further in the same direction makes a negligible dif-
erence. Furthermore, our consideration of stochastic extinctions
uring treatment impacts the ﬁndings. Since the cost of mutants
ffects their pre-treatment prevalence through selection, but does
ot affect their de novo appearance, neglecting cost-dependent
xtinctions during treatment gives a clear disadvantage to pre-
xistence, explaining the consistent directional effect of s found
reviously in the single-locus case (Ribeiro and Bonhoeffer, 2000).
tochastic losses also explain why we no longer ﬁnd that increasing
 always favours pre-existence (Ribeiro and Bonhoeffer, 2000).
aiting  time for the emergence of resistance
For clinical reasons, we may  be interested not only in the proba-
ility of resistance eventually emerging in a patient, but also in the
ime until this occurs. We  may  even anticipate being able to identify
he source of resistance (pre-existence or rescue) based on the time
t which resistance or viral rebound is detected. Analytically, we
an derive the waiting time distribution for the ﬁrst rescue mutant
o appear (Supplementary Material), and this can indeed give some
nsight into one component of the overall waiting time. However,
linically, it is more relevant to consider the time until the total
iral load rebounds to a detectable level. This is most easily inves-
igated by simulation, since the analysis is complicated by multiple
ounders of mutant lineages and competition for target cells as the
utant population grows. We  use a mock detection limit of 105
irions, which is 0.1% of the pre-treatment equilibrium number of
irions, for illustration. (For comparison, the detection limit of a
tandard HIV assay is 50 copies per mL  of plasma (Dornadula et al.,
999), whereas set-point viral loads mostly fall within the range of
03.5 to 105.5 copies per mL  in peripheral blood (Fraser et al., 2007).)
By comparing simulated time courses of viral load dynamics
nder treatment (Supplementary Fig. 5), it turns out that there is
ot a large difference in the waiting time to detection, whether
utants are pre-existing or arise during treatment. Fig. 9 clearly
hows the substantial overlap in the waiting time distributions
or these two cases. This similarity can be explained by the rel-
tively short waiting time for the ﬁrst rescue mutant to appear
see Supplementary Material), combined with an initial decline in
he pre-existing mutant population size as inﬂux from wild type
utations is reduced while target cells have not yet rebounded
ufﬁciently to support self-sustained mutant growth. That is, the
ime for mutant lineages to grow, rather than the time until lin-
ages are founded, seems to dominate the overall waiting time until
etection.
Nonetheless, we expect the degree of overlap of the waiting
ime distributions to be sensitive to parameter values. We  thus
nvestigate how the mean time of detection, provided resistance
merges, depends on drug efﬁcacy , cost of resistance s, and muta-
ion rate u (Supplementary Fig. 6). The waiting time turns out to
e insensitive to , and shows little differentiation between pre-
xistence and rescue. Both these effects can be explained by the
ominance of the mutant population growth phase – which is, to a
ood approximation, independent of the drug – in the overall wait-
ng time. An observed increase in waiting time with s can primarily
e explained by noting that a strain that replicates less efﬁciently
akes a longer time to reach a given population size. The differenti-
tion between pre-existence and rescue increases at low s because
f the large difference in starting population size: for instance, attion with efﬁcacy I = 0.8. (The simulations are the same as those in Supplementary
Fig.  5.)
s = 0.05, there are on average 600 pre-existing mutants at the time
treatment starts, versus zero rescue mutants. A similar effect occurs
at high mutation rate. The waiting time under the rescue scenario
declines slightly, due to the larger inﬂux of de novo mutants; how-
ever, this is not as large as the decline of waiting time under the
pre-existence scenario, in which the starting number of mutants
increases substantially.
Overall,  these results suggest that it may be difﬁcult to infer
whether outgrowth of resistance is due to pre-existing or rescue
mutants. We  expect the best possibility for differentiation to occur
when the mutation rate is high and the cost of resistance is low: in
this case, the large head start in population size gained by pre-
existing mutants implies that the waiting time until reaching a
detectable viral load tends to be lower. Although in some systems
it may  be possible to infer the source of resistance from the time
at which viral load rebounds (Adiwijaya et al., 2010), in general we
would proceed with caution in assuming that resistance that arises
quickly is due to pre-existence.
Discussion
Resistance  has repeatedly been observed to arise in patients
infected with fast-evolving pathogens subjected to the strong selec-
tive pressure of drug treatment. The source of resistance – whether
from genetic variation pre-existing in the pathogen population
before drug treatment begins, or arising during ongoing replication
under treatment – is an important line of investigation, both as a
basic evolutionary problem and as an issue with clinical relevance
for the optimal approach to treatment. Mathematical models play a
key role in understanding the intra-host dynamics of the pathogen.
In this study, we have expanded the investigation of the sources
of intra-host resistance to consider chronic viral pathogens with
differing life cycles. Our aim was to better understand how we  may
or may  not be able to generalize our understanding across diseases.
We ﬁnd that life cycle matters in a number of ways. Firstly, the
mutational and cost mechanisms affect the mutation-selection bal-
ance reached before drug treatment begins. Mutants with defects
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Table 2
Comparison of parameter values across three important chronic viral diseases:
human  immunodeﬁciency virus (HIV), hepatitis B virus (HBV), and hepatitis C
virus (HCV). Parameter estimates justifying these comparisons are provided in
Supplementary Material.
Parameter Comparison of diseases
Virion clearance rate, c HIV > HCV > HBV
Uninfected cell death rate, d HIV > HBV, HCV
Infected cell death rate, a HIV > HCV > HBV
Relative  infected cell death rate,  HCV > HIV, HBV
Basic  reproductive number, R00 HCV > HIV, HBV (?)
Pre-treatment infected cell population, y∗
S
HBV, HCV  HIV
Drug  efﬁcacy,  Depends on the drug(s)
Mutation  rate, u Depends on the per-base
pair  mutation rate, drug(s),00 H.K. Alexander, S. Bonhoeff
n persisting once generated will be present at lower frequen-
ies than those with defects in producing offspring. Secondly, the
echanism of cost affects the chance that a mutant lineage sur-
ives, i.e. escapes stochastic extinction. In a scenario of increasing
esources, corresponding to target cell rebound once the wild type
s suppressed by drug treatment, we ﬁnd that a mutant with
 survival cost (i.e. increased death rate) is less likely to have
escendants than a mutant with a productivity cost (i.e. decreased
ffspring production rate). This effect can be understood intuitively
s an advantage to mutants that can “wait for better times ahead” to
eproduce. We  conjecture that, when resource availability affects
birth” rate, this may  be a fairly general feature of stochastic
emographic processes in an environment of increasing resources,
hereas we would expect the opposite when resources are declin-
ng. (Note that our deﬁnition of cost across mechanisms implies
hat all mutants with a given magnitude of cost, s, have the same
robability of stochastic extinction, namely 1/RR0 = 1/(R00(1 − s)), in
 constant resource environment.) Thirdly, we ﬁnd that the inter-
ction between the step at which mutants are generated and the
tep at which the drug acts can have a major effect on the gen-
ration of rescue mutants once treatment begins. “Asynchronous”
rugs, which block the opposite step to which mutations occur,
eave a window of opportunity for existing sensitive-strain virus
o undergo the mutant-generating step of its life cycle uninhib-
ted, potentially producing virus which is subsequently resistant
o the drug. This suggests that it is important to target the primary
utant-generating step of a virus’s life cycle directly. We  expect the
recise effect of asynchronicity between drug action and mutation
o be sensitive to model details, such as pharmacokinetics, outside
ur present scope. Nonetheless, asynchronicity can be relevant in
eal systems: for instance, there are sources of HIV virions (e.g.
hose associated with follicular dendritic cells) that do not clear
ast (Blankson et al., 2002), and may  thus represent a signiﬁcant
ource of rescue mutations if drug treatment targets only virion
roduction and not cell infection.
These ﬁndings join an emerging body of literature making the
oint that life cycle details matter. For instance, recent studies
ave explored how the mechanism of replication with mutation
Loverdo et al., 2012) and the timing of virion release over an
nfected cell’s lifetime (Pearson et al., 2011) affect the fate of lin-
ages. A common theme is that such details matter when stochastic
ffects are signiﬁcant, as for an initially small population of a
rug-resistant pathogen. Although already more general than pre-
ious modelling efforts in this area, our model is still restricted
o “stamping machine” replication (Sanjuán et al., 2010), budding
elease of virions, and exponentially distributed infected cell life-
imes. Relaxing such assumptions is known to affect population
ynamics (Lloyd, 2001; Heffernan and Wahl, 2005; Pearson et al.,
011). Indeed, the intricacies of viral life cycles and drug action
ay call for a yet more detailed examination on the intracellular
evel, with links to the intercellular level. Incorporating an intra-
ellular description of HCV has already yielded novel insights into
opulation dynamics (Guedj and Neumann, 2010). We  expect fur-
her investigations along these lines, in directions of both greater
enerality and greater disease-speciﬁc detail, to continue painting a
ore nuanced picture of how life cycle details affect the emergence
f resistance.
Through substantial analytical understanding of parameter
ependencies, we were also able to identify regimes in which res-
ue plays a particularly important role in our system. Rescue tends
o be most signiﬁcant when drug efﬁcacy is low and the cost of
esistance is fairly high, mainly in agreement with previous ﬁnd-
ngs speciﬁc to HIV (Ribeiro and Bonhoeffer, 2000), though with the
aveat that neither rescue nor survival from pre-existence is possi-
le once cost is too high. Since empirical observations suggest costs
f resistance may  indeed be high (see Supplementary Material),and  cost, s genetic constraints, and
mechanism  of resistance
we would not downplay the importance of this parameter range.
Furthermore, by explicitly considering probabilities of emergence
instead of the proxy of expected numbers of mutants, the relative
contribution of rescue may  be considered largest at some interme-
diate range of total mutational inﬂux, rather than independent of
mutation rate (Ribeiro and Bonhoeffer, 2000). Our consideration
of stochastic extinctions also enables us to say that rescue may
be more important than previously thought, since mutants arising
later during the course of target cell rebound have a better chance
of survival. In particular, in contrast to earlier work (Ribeiro and
Bonhoeffer, 2000), we predict that higher infected cell death rate
does not always favour pre-existence. Indeed, there can be complex
interaction effects among parameters.
With our understanding of parameter dependencies, we  can
compare three important chronic viral diseases: HIV, HBV, and HCV.
Table 2 summarizes how parameters vary across these diseases;
see Supplementary Material for quantitative details and references.
Interestingly, different factors act in different directions, such that
no disease consistently appears more vulnerable to the emergence
of resistance or more prone to a particular source. For instance,
HCV has a larger infected cell population size than HIV, but also a
higher relative infected cell death rate. We  can also say that some
of the differences observed among these diseases are unlikely to
play a large role. For example, free virus clears more quickly in HIV
than in HCV; however, independently of effects on R00, we expect
this distinction to be unimportant. Furthermore, large differences
in infected cell death rate among the diseases are moderated by
the fact that uninfected cell death rates follow a similar pattern.
Of course, the speed with which resistance emerges in real time
does depend on the absolute turnover rates, as measured by d.
The intertwined inﬂuences of mutation rate and cost are more dif-
ﬁcult to interpret. Available evidence indicates that the per-base
pair mutation rate is fairly similar across these viruses. However,
for any particular drug, the genetic basis of resistance (e.g. num-
ber of base changes required and number of possibilities yielding a
resistant phenotype) and its phenotypic effects give rise to a partic-
ular effective mutation rate to the resistance allele and a particular
cost. Furthermore, mutations may  have pleiotropic effects, partic-
ularly when genes are encoded by overlapping reading frames, as
in HBV, which may  thus face more stringent constraints (Soriano
et al., 2008). This could give rise to a lower effective (viable) muta-
tion rate to resistance and/or higher costs. Finally, we note that
some parameters, including viral set-point (pre-treatment popu-
lation size) for HIV and infected cell lifetime for HBV, are known
to vary widely across patients. This suggests that different patients
with the same disease will be at varying risk for the emergence of
resistance and the relative importance of rescue.
The source of drug resistance is difﬁcult to investigate empiri-
cally, particularly in vivo, which is why mathematical modelling has
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layed such an important role in developing an understanding of
his problem. Accordingly, it is difﬁcult to test many of the detailed
odel results empirically. Nonetheless, our theoretical work
uggests a few possibilities. One key prediction is that drug efﬁcacy
as very little effect on the probability or timing at which pre-
xisting drug-resistant mutants arise (in absolute numbers). This
dea could perhaps be tested in an animal model by viral infection
ollowed by treatment at varying drug dosages. If the emergence
f resistance is independent of dose, it can likely be attributed to
re-existence. Conversely, however, an observed dependence may
e explained not only by a predominant contribution of rescue,
ut also by mutants being only partially resistant. Another insight
rom our model relates to the time on treatment until resistance is
etected. Our analysis of waiting times suggests that fast-emerging
esistance cannot necessarily be attributed to pre-existence. We
ote, however, that our model assumes an idealized situation in
hich the drug(s) are effective at all times, in all anatomical com-
artments and cell types. Patient data at sufﬁcient time resolution
ould indicate whether resistance actually emerges on a completely
ifferent time scale than our models predicts, which would indi-
ate that other mechanisms, such as patient adherence issues or
eservoirs of infected cells not responsive to drug, are important.
ther infected cell populations could in principle also be analysed
y our model, so long as they are declining, even if slowly. Indeed,
e expect that such populations could make a disproportionate
ontribution to rescue, since mutants arising later face a more
avourable level of target cells. Naturally, we would also expect
actors such as the activation of latently infected cells in HIV to
dd an ongoing source of rescue at a low rate. In a complemen-
ary approach, another recent study considered these long-term
ources but neglected the dynamic short-term decline phase of the
rug-sensitive population (Pennings, 2012).
Our results also have signiﬁcance for researchers interested in
sing theory to develop more accurate quantiﬁcations, and suggest
irections for further empirical work in vitro. Our model elucidates
hich parameters are most important to measure in order to better
redict the emergence of drug resistance. We  also point out when
 detailed understanding of life cycle is signiﬁcant. For instance,
t is important to identify the step(s) of the life cycle affected by
ostly resistance, not only the impact on an overall measure of ﬁt-
ess. This is particularly signiﬁcant if estimated ﬁtness costs are
igh. We  also caution that mutation rate estimates obtained from
requency measurements at the mutation-selection balance may
e affected by the mechanism of cost; speciﬁcally, the mutation
ate may  be underestimated if costs are borne in part by reduced
urvival instead of productivity.
Returning to a more general theoretical context, understand-
ng the source of intra-host emergence of resistance remains an
mportant question across diseases, not only chronic viral infec-
ions. Interestingly, there have been a few convergent results in
ery different models, besides those presented here and previously
or viral pathogens. A study of resistance to targeted chemother-
py in cancerous tumours concluded that pre-existence was  more
ikely than rescue, except in the unrealistic case of a single, very
neffective drug (Komarova and Wodarz, 2005); no cost of resis-
ance was incorporated here. A more generic model (Orr and
nckless, 2008) described a population declining in size follow-
ng an environmental change that reduces the ﬁtness of the wild
ype, with the possibility of rescue through outgrowth of a vari-
nt more ﬁt in the new environment. “Standing genetic variation”
analogous to pre-existing mutants) was the more likely source of
escue than mutants arising after the environmental change, pro-
ided the deleterious effect of this mutation before the change
as sufﬁciently small (Orr and Unckless, 2008). These parallel con-
lusions motivate further investigation into their generality and
ossible exceptions.idemics 4 (2012) 187–202 201
To this end, the mathematical machinery developed here for
analytical approximations could be more broadly useful in explor-
ing various life cycles and even different diseases, as the general
techniques are widely transferable. Some extensions, such as
incorporating partial resistance or differing costs in the presence
or absence of drug, would be straightforward to incorporate into
our model. Others, such as time-varying drug efﬁcacy (due to
pharmacokinetics and therapy adherence patterns) and multiple
mutational steps (including primary resistance to multiple drugs,
as well as compensatory mutations), will require larger extensions.
Incorporating non-equilibrium dynamics, as in acute infections or
slow-turnover cellular compartments, remains challenging. Acute
infections, such as inﬂuenza, have the further complication that
the time varying nature of the immune response, which ulti-
mately leads to clearance even without drug treatment, cannot
be neglected. However, we  expect our mathematical approach
to transfer readily to other diseases in which dynamics have
equilibrated before treatment begins, and in which resistance sub-
sequently emerges stochastically in an environment of possibly
changing resource availability. In this way  we  can gain some analyt-
ical understanding of parameter dependencies in the system, and
hence insight into the important factors driving the emergence of
drug resistance.
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